Drug · CHEMBL830
EFLORNITHINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EFLORNITHINE. Drugs and targets, record CHEMBL830. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL830
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 5 of its 27 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ODC1 | Ornithine decarboxylase | Ornithine decarboxylase inhibitor | INHIBITOR | https://conductscience.org/library/genes/4953 |
Source ChEMBL
Diseases27
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| neuroblastoma | Phase 2 | ClinicalTrials.gov | 8 | 7 | https://conductscience.org/library/drugs?q=MONDO_0005072 |
| human African trypanosomiasis | Approval | TTD | 5 | 4 | https://conductscience.org/library/drugs?q=MONDO_0005459 |
| astrocytoma (excluding glioblastoma) | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0019781 |
| prostate cancer | Phase 2 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| classic familial adenomatous polyposis | Phase 3 | ClinicalTrials.gov and TTD | 3 | 1 | https://conductscience.org/library/drugs?q=MONDO_0021055 |
| Hirsutism | Approval | EMA Human Drugs | 2 | 1 | https://conductscience.org/library/drugs?q=HP_0001007 |
| Ewing sarcoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0012817 |
| anaplastic astrocytoma | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0016684 |
| bladder transitional cell carcinoma | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005611 |
| breast cancer | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
1 to 10 of 27Source Open Targets
See all 27 diseasesTrials35
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00118365 | Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps | Phase 3 | 375 | 2015-01-22 | eflornithine | Its name | ClinicalTrials.gov |
| NCT00033371 | Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis | Phase 2 | 205 | 2015-02-04 | eflornithine | Its name | ClinicalTrials.gov |
| NCT01483144 | Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP) | Phase 3 | 171 | 2021-06-08 | eflornithine | Its name | ClinicalTrials.gov |
| NCT02395666 | Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission | Phase 2 | 140 | 2020-04-03 | eflornithine | Its name | ClinicalTrials.gov |
| NCT00983580 | Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer | Phase 2 | 107 | 2018-04-30 | eflornithine | Its name | ClinicalTrials.gov |
| NCT03794349 | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | Phase 2 | 94 | 2026-01-21 | eflornithine | Its name | ClinicalTrials.gov |
| NCT02794428 | Chemoprevention of Gastric Carcinogenesis | Phase 2 | 91 | 2024-04-05 | eflornithine | Its name | ClinicalTrials.gov |
| NCT00006101 | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | Phase 2 | 76 | 2018-04-12 | eflornithine | Its name | ClinicalTrials.gov |
| NCT01059071 | Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide | Phase 1 | 21 | 2016-06-20 | difluoromethylornithine | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00906880 | Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase | Phase 4 | 630 | eflornithine | Its name | ClinicalTrials.gov |
1 to 10 of 35
See all 35 trialsComparisons in its trials11
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (Eflornithine and Sulindac) vs Arm II (Placebo): Adverse Events With a Grade of 3 and Above | 46 of 191 | 37 of 184 | 375 | NCT00118365 | Trial comparisons |
| Arm I (Eflornithine and Sulindac) vs Arm II (Placebo): serious adverse events | 41 of 191 | 28 of 184 | 375 | NCT00118365 | Trial comparisons |
| Arm I: Celecoxib and Placebo vs Arm II: Celecoxib and Eflornithine: serious adverse events | 0 of 55 | 3 of 57 | 112 | NCT00033371 | Trial comparisons |
| Arm I (Acetylsalicylic Acid and Eflornithine) vs Arm II (Placebo): deaths from any cause | 0 of 52 | 0 of 50 | 102 | NCT00983580 | Trial comparisons |
| Arm I (Acetylsalicylic Acid and Eflornithine) vs Arm II (Placebo): serious adverse events | 0 of 52 | 1 of 50 | 102 | NCT00983580 | Trial comparisons |
| Eflornithine vs Eflornithine Placebo: deaths from any cause | 0 of 45 | 0 of 46 | 91 | NCT02794428 | Trial comparisons |
| Eflornithine vs Eflornithine Placebo: serious adverse events | 2 of 45 | 2 of 46 | 91 | NCT02794428 | Trial comparisons |
| Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): deaths from any cause | 13 of 44 | 19 of 47 | 91 | NCT03794349 | Trial comparisons |
| Regimen A (Chemotherapy, Dinutuximab, Sargramostim) vs Regimen B (Eflornithine, Chemotherapy, Dinutuximab): serious adverse events | 3 of 44 | 20 of 47 | 91 | NCT03794349 | Trial comparisons |
| Eflornithine vs Placebo: deaths from any cause | 0 of 38 | 0 of 38 | 76 | NCT00006101 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials25
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL830
GET https://conductscience.org/api/drugs/v1/CHEMBL830/diseases?page=2